Y Parc1, S Gueroult, N Mourra, L Serfaty, J-F Fléjou, E Tiret, R Parc. 1. Department of Digestive Surgery, Hospital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, University Pierre et Marie Curie, 184 rue du faubourg Saint-Antoine, 75012 Paris, France. yann.parc@sat.ap-hop-paris.fr
Abstract
BACKGROUND: Microsatellite instability (MSI) has been identified as a factor with good prognosis and chemosensitivity in stage III C colon cancer. The purpose of this study was to evaluate the routine use of immunohistochemical analysis (immunohistochemical staining of MSH2 and MLH1) to identify T3N0M0 (stage II) colon cancer with MSI and assess the prognostic value of this analysis. The study was conducted in a large cohort of patients in a single institution who had a curatively resected T3N0M0 colon cancer and were not receiving adjuvant therapy. METHODS: Between June 1995 and December 2001, 142 patients (77 females) with a mean age of 68 years, suffering from T3N0M0 colon cancer curatively resected and not receiving adjuvant therapy, were checked in terms of their follow up status. The results of colonoscopy, hepatic ultrasonography, chest x ray, and blood carcinoembryological antigen were noted. All tumours were immunohistochemically stained for MSH2 and MLH1. Perineural invasion, lymphovascular invasion, and the presence of vascular neoplastic emboli were assessed. RESULTS: Twenty four patients (17%) had MSI tumours. Patients with MSI and microsatellite stable (MSS) tumours did not differ in terms of age, perineural or lymphovascular invasion, or the presence of vascular neoplastic emboli. Patients with MSI tumours were more frequently female (18/24 v 60/118; p = 0.001) and more frequently suffered from right sided cancer (19/24 v 58/118; p<0.001). Patients with MSI tumours exhibited significantly better recurrence free survival than those with MSS tumours (p = 0.02). Cox analysis identified age and MSI determined by immunohistochemistry as independent predictive factors of good prognosis (p = 0.009, odds ratio 1.04 (1.01-1.08); p = 0.04, odds ratio 7.9 (1.05-59.6)). CONCLUSIONS: MSI determined by immunohistochemistry is an independent predictive factor of good prognosis in T3N0M0 colon cancer. The prognosis for MSI T3N0M0 colon cancer is excellent and chemotherapy should not be proposed in these patients as immunohistochemical analysis produces rapid results.
BACKGROUND: Microsatellite instability (MSI) has been identified as a factor with good prognosis and chemosensitivity in stage III C colon cancer. The purpose of this study was to evaluate the routine use of immunohistochemical analysis (immunohistochemical staining of MSH2 and MLH1) to identify T3N0M0 (stage II) colon cancer with MSI and assess the prognostic value of this analysis. The study was conducted in a large cohort of patients in a single institution who had a curatively resected T3N0M0 colon cancer and were not receiving adjuvant therapy. METHODS: Between June 1995 and December 2001, 142 patients (77 females) with a mean age of 68 years, suffering from T3N0M0 colon cancer curatively resected and not receiving adjuvant therapy, were checked in terms of their follow up status. The results of colonoscopy, hepatic ultrasonography, chest x ray, and blood carcinoembryological antigen were noted. All tumours were immunohistochemically stained for MSH2 and MLH1. Perineural invasion, lymphovascular invasion, and the presence of vascular neoplastic emboli were assessed. RESULTS: Twenty four patients (17%) had MSI tumours. Patients with MSI and microsatellite stable (MSS) tumours did not differ in terms of age, perineural or lymphovascular invasion, or the presence of vascular neoplastic emboli. Patients with MSI tumours were more frequently female (18/24 v 60/118; p = 0.001) and more frequently suffered from right sided cancer (19/24 v 58/118; p<0.001). Patients with MSI tumours exhibited significantly better recurrence free survival than those with MSS tumours (p = 0.02). Cox analysis identified age and MSI determined by immunohistochemistry as independent predictive factors of good prognosis (p = 0.009, odds ratio 1.04 (1.01-1.08); p = 0.04, odds ratio 7.9 (1.05-59.6)). CONCLUSIONS: MSI determined by immunohistochemistry is an independent predictive factor of good prognosis in T3N0M0 colon cancer. The prognosis for MSI T3N0M0 colon cancer is excellent and chemotherapy should not be proposed in these patients as immunohistochemical analysis produces rapid results.
Authors: L Cawkwell; S Gray; H Murgatroyd; F Sutherland; L Haine; M Longfellow; S O'Loughlin; D Cross; O Kronborg; C Fenger; N Mapstone; M Dixon; P Quirke Journal: Gut Date: 1999-09 Impact factor: 23.059
Authors: K C Halling; A J French; S K McDonnell; L J Burgart; D J Schaid; B J Peterson; L Moon-Tasson; M R Mahoney; D J Sargent; M J O'Connell; T E Witzig; G H Farr; R M Goldberg; S N Thibodeau Journal: J Natl Cancer Inst Date: 1999-08-04 Impact factor: 13.506
Authors: Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger Journal: N Engl J Med Date: 2003-07-17 Impact factor: 91.245
Authors: R A Lothe; P Peltomäki; G I Meling; L A Aaltonen; M Nyström-Lahti; L Pylkkänen; K Heimdal; T I Andersen; P Møller; T O Rognum Journal: Cancer Res Date: 1993-12-15 Impact factor: 12.701
Authors: R Jover; P Zapater; A Castells; X Llor; M Andreu; J Cubiella; V Piñol; R M Xicola; L Bujanda; J M Reñé; J Clofent; X Bessa; J D Morillas; D Nicolás-Pérez; A Payá; C Alenda Journal: Gut Date: 2005-11-18 Impact factor: 23.059
Authors: Tao Fu; Emmanouil P Pappou; Angela A Guzzetta; Marilia de Freitas Calmon; Lifeng Sun; Alexander Herrera; Fan Li; Christopher L Wolfgang; Stephen B Baylin; Christine A Iacobuzio-Donahue; Weidong Tong; Nita Ahuja Journal: Ann Surg Date: 2016-02 Impact factor: 12.969
Authors: Lisa Lutz; Ingrid Coutiño Fitzner; Theresa Ahrens; Anna-Lena Geißler; Frank Makowiec; Ulrich T Hopt; Lioudmila Bogatyreva; Dieter Hauschke; Martin Werner; Silke Lassmann Journal: Am J Cancer Res Date: 2016-02-15 Impact factor: 6.166
Authors: E R Nijhuis; H W Nijman; K A Oien; A Bell; K A ten Hoor; N Reesink-Peters; H M Boezen; H Hollema; A G J van der Zee Journal: J Clin Pathol Date: 2007-07 Impact factor: 3.411
Authors: Jennifer A Chan; Jeffrey A Meyerhardt; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James Thomas; Paul Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Robert S Warren; Monica Bertagnolli; Charles S Fuchs Journal: JAMA Date: 2008-06-04 Impact factor: 56.272
Authors: Thierry André; Pauline Afchain; Alain Barrier; Pierre Blanchard; Annette K Larsen; Christophe Tournigand; Christophe Louvet; Aimery de Gramont Journal: Gastrointest Cancer Res Date: 2007-05